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Abstract
Nanoprecipitation technique, also named solvent injection, spontaneous emulsi-
fication, solvent displacement, solvent diffusion, interfacial deposition, mixing-
induced nanoprecipitation, or flash nanoprecipitation, is recognized as a useful and
versatile strategy for trapping active molecules on the submicron and nanoscale
levels. Thus, these particles could be intended among others, for developing inno-
vative pharmaceutical products bearing advantages as controlled drug release, tar-
get therapeutic performance, or improved stability and organoleptic properties. On
this basis, this chapter offers readers a comprehensive revision of the state of the art
in research on carriers to be used for pharmaceutical applications and developed by
the nanoprecipitation method. In this sense, the starting materials, the particle
characteristics, and the in vitro and in vivo performances of the most representative
of these carriers, i.e., polymer, lipid, and hybrid particles have been analyzed in a
comparative way searching for a general view of the obtained behaviors.
Keywords: nanoprecipitation, nanoparticles, colloidal carriers, drug delivery
systems, lipid carriers, hybrid nanoparticles
1. Introduction
Nanoprecipitation is a technique to incorporate active molecules into colloidal
drug delivery systems, patented by Fessi et al. [1, 2], which attracts attention for
developing pharmaceutical products mainly due to the simplicity of its procedure
[3]. The obtained particles enable the optimization of the drug in vivo therapeutic
performance exhibiting, for example, controlled release behaviors, target delivery,
and better stability in biological fluids, which means major mean residence times,
half-lives increased, and more efficient addressing of the actives toward the differ-
ent body tissues. Consequently, less toxicity and minor secondary effects are
expected.
Some of the research works undertaken during the last years have proposed the
vectorization in nanoparticles, via nanoprecipitation, of hydrophobic active mole-
cules, mainly exhibiting logP values higher than 3. They include antineoplastics
(e.g., doxorubicin [4], paclitaxel [5, 6], docetaxel [7, 8], methotrexate [9], triptolide
[6], cucurbitacin [10], and sorafenib [11]), antiretrovirals (e.g., efavirenz [12] and
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nevirapine [13]), immune suppressants (mycophenolate [14]), anti-inflammatories
(clobetasol [15], fluticasone propionate [16], dexamethasone [17, 18], and
diclofenac [19]), antimicrobial and antifungal agents (polymyxin B [20],
amphotericin B [21], itraconazole [22], and linezolid [23]), antihyperlipidemics
(fenofibrate [24, 25]), anesthetics (tetracaine [26] and ketamine [27]),
antihypertensives (nimodipine [28] and atenolol [29]), vitamins or their precursors
(β-carotene [30] and vitamin E [31]), and antioxidants (quercetin [14, 32]).
Likewise, although in a much smaller number, hydrophilic active molecules such
alendronate [33], N-acetylcysteine [34], and calcein [35], have been investigated.
Moreover, natural extracts such as Brazilian red propolis extract [36] and essential
oils [37] have also been incorporated into polymeric nanoparticles.
Practical matters as the possibility to use solvents of low toxic potential, the
simple procedure, the low energy consumption required, and the feasibility to
obtain particles from diverse compositions are also highlighted among the pros of
the nanoprecipitation method when carriers at the submicron and nanometric
scales are intended [3, 38]. Most of the nanoparticulated drug delivery systems
reported as prepared by nanoprecipitation have been developed by using the phys-
icochemical principles governing this technique, primarily those who underpin the
precipitation of materials from the mixture of a solvent/non-solvent for the
involved material. They include in their majority, polymer, lipid, and hybrid
nanoparticles; therefore, this review will be fundamentally focused on them. Nev-
ertheless, some interesting developments of nanoparticles prepared by nanopreci-
pitation have been reported as well. For example, Arizaga et al. [39] and Villela et al.
[40] entrapped magnetic nanoparticles inside polymeric particles, Fan et al. [41]
designed spatially controlled release multistage carriers via the complexation of
dendrimers with gelatin, and Allen et al. [35] entrapped hydrophobic and hydro-
philic active molecules into polymersomes. Likewise, modifications to facilitate the
industrial scaling-up of the preparation process have been investigated by
Charcosset et al. [42] and D’Oria et al. [43] who developed procedures based on the
use of a membrane contactor. On its part, Valente et al. [44] and Tao et al. [45]
propose controllable mixing devices such as microfluidic mixer systems that allow
continuous and scalable processes for the synthesis of the particles.
Reviews published to date dealing with the nanoprecipitation technique provide
valuable information from different standpoints. For example, regarding the role of
the obtained particles as drug delivery systems and their applications in medicine,
Martínez et al. [46] highlighted their ability for carrying either natural products or
actives obtained via chemical synthesis. On the other hand, with respect to the
study of nanoprecipitation as a physicochemical process, Mora-Huertas et al. [47]
revised the influence of both the formulation and the work conditions used to
prepare nanoparticles. In this case, data available in scientific reports supplemented
with a systematic study of the nanoprecipitation method led to an approximation to
the particle formation mechanisms and identify the factors influencing the particle
properties. Recently, Saad and Prud’homme [48] deepened on the physicochemical
principles of the nanoparticle formation when amphiphilic block copolymers are
used as stabilizing agents (named flash nanoprecipitation). They focused on the key
variables determining the nucleation and growth phenomena related to the particle
formation, particularly the supersaturation condition, the mixing step, and the used
solvents and stabilizing agents.
Based on the above, the present chapter revises the generalities of the
nanoprecipitation technique such as the physicochemical aspects involved, some of
the starting materials used to obtain polymer, lipid, and hybrid nanoparticles, and
their characteristics. Then, the pharmacokinetic behaviors, safety evaluations, and
efficacy tests are analyzed. It is our interest to provide readers with a
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comprehensive view about the nanoprecipitation as a technique to prepare
nanocarriers and its potentialities for developing innovative pharmaceutical
products.
2. Physicochemical fundamentals of the nanoprecipitation technique
To prepare nanoparticles via the nanoprecipitation technique, two miscible sol-
vents are used, one of them being a good solvent (usually an organic solvent as
ethanol, isopropanol, or acetone) and the other one acting as a non-solvent for the
material that will form the particle (i.e., polymer, lipid, etc.), e.g., water. In general,
as shown in Figure 1, the nanoprecipitation procedure requires the preparation of
an organic phase and a non-solvent phase, frequently named aqueous phase, both
guaranteeing the total solubility of all the starting materials. In this sense, the
organic phase could contain polymers or solid and liquid lipids, surfactants of low
HLB value, and active molecules dissolved in a solvent or mixture of organic sol-
vents. The solubility in the solvent of the active molecule to be entrapped is one of
the factors limiting the drug loading of the particles. On its part, the non-solvent
phase mainly includes stabilizing agents solubilized in water, which allows the
particle formation and the physical stability of the system [2]. Nonetheless, the
preparation of particles without stabilizing agents has been reported. In these cases,
for example, isoprenoid chains are linked to the active molecule making it easy to
form the nanoparticle because of its amphiphilic nature [49].
Nanoparticles are spontaneously formed when the organic phase is dropped or
added in a one-shot to the aqueous phase. Indeed, nanoprecipitation is a robust
process and operational conditions used to prepare the particles do not seem to have
a marked influence on the obtained particle size and polydispersity index. On the
contrary, the variables linked to the used formulation appear as determinants of the
characteristics of the nanosized system, mainly the nature and concentration of the
starting materials [47]. This might be closely related to the proposed mechanisms to
Figure 1.
General view of the preparation of polymer, lipid, and hybrid particles by nanoprecipitation summarizing the
work conditions commonly reported (PNC: polymeric nanocapsules; PNS: polymeric nanospheres; SLN: solid
lipid nanoparticles; HNP: hybrid nanoparticles; RT: room temperature).
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form the particles by the nanoprecipitation technique. As a basic premise, only
specific polymer/solvent/non-solvent ratios, where the polymer is in low concen-
trations and the solvent is in low proportion with respect to the nonsolvent, lead to
particles at the nano- and submicron levels [50]. Thus, on the one hand, the
mechanical approach states that when the phases are mixed, the organic phase is
successively broken as drops within the aqueous phase due to the interfacial turbu-
lence and thermal inequalities in the system because of the mutual miscibility
between the solvent and the non-solvent and their different interfacial tensions
(Gibbs-Marangoni effect) [51]. This fragmentation process will occur until the
difference in interfacial tensions is minimized and the organic solvent migrates
from the drops having a submicron size, which creates a non-solubility condition
for the material causing the precipitation of the particles. On the other hand, a
mechanism based on the chemical instability of the system has also been proposed
(“ouzo effect”). In this case, when the phases are mixed, supersaturation of the
molecules forming the particles is caused as the organic solvent migrates toward the
aqueous phase, allowing the formation of “protoparticles” that grow following the
classical nucleation-and-growth process [48, 52, 53]. It seems that depending on the
formulation to prepare the nanoparticles, one of those mechanisms could predom-
inate during the nanoprecipitation, and consequently, the adequate work conditions
should be defined for allowing the spontaneous formation of submicron or nano-
scale particle sizes exhibiting the smallest polydispersity indexes. Difficulties asso-
ciated with the standardization of the procedure of nanoprecipitation result in the
polymer aggregation yielding wide and asymmetric particle size distributions. For
example, polymer aggregates are evidenced because of a concentrated organic
phase, high organic phase ratio, low concentration of stabilizing agent, and poor
mixing of the phases [47].
It is worth clarifying that in-depth studies on how particles are formed via the
nanoprecipitation technique and the operating variables determining their charac-
teristics have been carried out by using polymeric systems. Regarding lipid
nanoparticles, only systematic studies have been reported to aid in understanding
the variables that influence the preparation of the carriers; among them, the con-
tributions of Martínez-Acevedo et al. [54] on the influence of the used recipe and
Noriega-Pelaez [55] on the study of the particle preparation process are highlighted.
Concerning the hybrid particles, research works to date have focused primarily on
the impact of the starting materials on the particle characteristics [5, 9, 12, 23, 56].
Once the nanocarriers are formed, the particle dispersions are further processed
to purified and concentrate them. To this end, rotary evaporation [14, 18, 22–24, 31,
55] and centrifugation [5, 6, 12, 13, 15, 16, 23, 25, 27–29, 36, 56, 57] are the most used
methods; however, filtration [4, 6, 16, 18, 24] and dialysis [7–9, 21, 27, 34] have also
been reported. Likewise, lyophilization is the preferred technique to stabilize the
nanoparticles, although the storage to low temperatures has been used to preserve
the aqueous dispersions [5, 8, 9, 13, 21, 29].
3. Starting materials and general characteristics of particles prepared by
nanoprecipitation
As mentioned above, although different types of carriers intended for pharma-
ceutical applications can be prepared via nanoprecipitation, only polymer, lipid,
and hybrid particles were chosen to be analyzed in detail because of the amount of
reported research works to date. Polymeric nanoparticles are classified as polymeric
nanospheres (PNS) and polymeric nanocapsules (PNC). The first ones correspond
to a solid matrix conformed by the used polymers and other components, e.g.,
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active molecules and lipophilic surfactants. On its part, the structure of the
nanocapsules is proposed as an oil core surrounded by a polymeric shell. Approxi-
mately, 90% of the research works published on the preparation of polymeric
nanoparticles via the nanoprecipitation technique are devoted to the obtention of
nanospheres.
With respect to lipid nanoparticles, both solid lipid nanoparticles (SLN) and
nanostructured lipid carriers (NLC) have been investigated, although almost 85% of
the research works deal with SLN. Lipids nanoparticles are composed of a lipid
matrix that is supposed to be surrounded by stabilizing agents. In the case of SLN,
the lipid matrix is exclusively formed by solid lipids, while the lipid matrix of NLC
is composed of solid and liquid lipids. It seems that the liquid lipid in NLC favors the
entrapment efficiency of the active molecules [58].
Regarding hybrid nanoparticles, they are made from both polymers chemically
modified with lipids (e.g., 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-
methoxy polyethylene glycol—DSPE-PEG) or the physical mixture between poly-
mers and lipid components (e.g., PLGA and soy lecithin). Nevertheless, in the latter
case, although the qualitative recipe is similar to that for polymeric particles, higher
concentrations of solid lipids are used to prepare hybrid particles (i.e., lipid con-
centrations range between 20 and 50% for hybrid particles and between 1 and 5%
for polymeric nanoparticles).
3.1 Starting materials
Figure 2 shows in a comparative way the reported starting materials used to
prepare the different types of particles via nanoprecipitation. As can be seen, PLGA,
PCL, and PLA are the most used polymers to prepare polymeric nanoparticles and
when these polymers are chemically modified with, for example, PEG, stealth
polymeric nanoparticles can be obtained [16, 17, 27]. Surfactants of low HLB value,
e.g., soy phospholipids, could be added to the organic phase for facilitating the
particle formation [19, 31] and, if nanocapsules are intended, castor oil, sesame oil,
caprylic capric triglycerides, and caprylic capric triglyceride PEG-4 esters are part
of the organic phase. Acetone appears as the preferred organic solvent of the
organic phase and the non-solvent is water. Thus, the aqueous phases are solutions
of stabilizing agents as poloxamer, polyvinyl alcohol, and polysorbate 80, which
prevent the particle aggregation phenomena. Likewise, aqueous phases can only be
water [16] or phosphate buffer [27, 59].
To prepare SLN, fatty acids and their glyceryl esters are frequently used as lipids
(e.g., glyceryl monostearate, tristearate, behenate, and dilaurate); they are dis-
persed at a molecular level in organic solvents such as acetone and ethanol for
obtaining the organic phase. As in the case of polymeric nanoparticles, phospho-
lipids can be used to favor the particle formation and, to make NLC, liquid lipids as
caprylic capric triglycerides are also dissolved in the organic phase. With respect to
the non-solvent phase, aqueous solutions of stabilizing agents of varied nature are
reported. Among them, surfactants as those mentioned for polymeric nanoparticles,
proteins such as sodium caseinate and lactoferrin, and osmotic active compounds
such as glucose and magnesium sulfate have been investigated.
Hybrid nanoparticles were designed to integrate the favorable characteristics of
both polymeric and lipid systems and overcome their drawbacks [34]. These sys-
tems are proposed as an inner polymeric core surrounded by a lipid shell [60]. To
obtain it, as is the rule in nanoprecipitation, organic and aqueous phases are
designed so that solubility of the starting materials is guaranteed. As one of the
strategies to prepare hybrid particles is employing polymers chemically modified
with lipids (e.g., DSPE-PEG-NH2), they behave as amphiphilic compounds that
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could form part of any of the phases according to their solubility. On the contrary, if
a physical mixture of polymer and lipid is used, they are dissolved in the organic
phase. Unlike polymeric and lipid particles, acetonitrile is reported as the most used
organic solvent for preparing hybrid nanoparticles. Another interesting matter of
the recipe to prepare hybrid nanoparticles is the versatile composition of the aque-
ous phase. In this sense, for example, lecithin and cholesterol can be dissolved in
ethanol and then incorporated in the aqueous phase that could contain surfactants
such as polysorbate and poloxamer. Likewise, dispersions of surfactants, proteins,
or buffers were tested as the aqueous phase.
Figure 2.
Starting materials reported as used to prepare the organic and aqueous phases for obtaining polymer, lipid, and
hybrid nanoparticles by the nanoprecipitation technique. Number of times reported for each starting material
considering a total of 18, 11, and 13 research works for polymer, lipid, and hybrid particles, respectively
[PLGA: poly(lactic-co-glycolic acid); PCL: polycaprolactone; PLA: poly(lactic acid); PEG: polyethylene glycol;
HPMC: hydroxypropyl methylcellulose; DMSO: dimethyl sulfoxide; CAP: cellulose acetate phthalate; EtOH:
ethanol; ACN: acetonitrile; MetOH: methanol; DMF: dimethylformamide; DCM: dichloromethane; THF:
tetrahydrofuran; MEK: methyl ethyl ketone; H-b-pBG: hyaluronan poly(γ-benzyl-L-glutamate); PBS:
phosphate-buffered saline; SDS: sodium dodecyl sulfate; GMS: glycerol monostearate; TPGS: tocopheryl
polyethylene glycol succinate; PVA: polyvinyl alcohol; Tf-PEG-OA: transferrin-poly(ethylene glycol)-oleic acid;
Tf: transferrin; HSA: human serum albumin; DSPE-PEG: 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-
N-[methoxy(polyethylene glycol)]].
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3.2 General characteristics of the particles
Regardless of the type of particle, the shape, the particle size, the drug
entrapment, and loading, and the zeta potential are among the crucial properties
determining their pharmaceutical performance [61].
3.2.1 Shape
Polymeric and hybrid particles prepared by using the nanoprecipitation technique
exhibit spherical shape as it is revealed by techniques of microscopy, mainly scanning
electron (SEM), transmission electron (TEM), atomic force (AFM), and field emis-
sion scanning microscopies (FESEM). To investigate the shape of lipid nanoparticles
in most cases, the same techniques were used, and spherical shapes were also
reported. However, lipids might be melted during the sample examination destroying
their native characteristics; consequently, controversial results could be obtained. For
example, platelet shapes for SLN [62, 63] and structures with the liquid lipid located
on the surface of the particles in the form of plates for NLC [64, 65] have been
reported by using cryo-TEM and freeze-fracture TEM. Nevertheless, Dong et al. [24]
report spherical shape from the analysis of SLN by using Cryo-FESEM.
3.2.2 Particle size
In general, the mean sizes, usually measured by dynamic light scattering, vary
between less than 100 and 300 nm with PDI values below 0.4 (Figure 3A and B).
It seems that polymeric nanocapsules and specially hybrid nanoparticles are the
smallest; perhaps, any type of structural arrangement among the lipids and poly-
mers could favor a better consolidation of the particle. With respect to lipid carriers,
the platelet shapes as the lipids crystallize inside the particle could explain their high
polydispersity [66].
3.2.3 Drug entrapment efficiency
Regarding the entrapment efficiency (Figure 3C), clear differences are identified
among the carriers. Thus, polymeric nanocapsules entrap almost the totality of the
active molecule in contrast with 40% attained by the SNL. As remarked byWestesen
et al. [67], Pardeike et al. [68], and Weber et al. [69], when preparing SLN the
solidification and the progressive crystallization of the lipid in more stable forms
could lead the expulsion of the active substances whether during the particle forma-
tion or its consolidation. This results in eventual instabilities of the particle dispersions
and, as evidenced in this case, low entrapment efficiency and loading of active
molecules. On the other hand, as shown in Figure 3D, the best results of drug loading
are reported for hybrid nanoparticles; active molecules could be located both in the
polymeric core and the lipid layer of the particles maximizing their loading efficiency.
3.2.4 Physicochemical stability
Stability of the particle dispersions has been investigated by using refrigerated
storage [6, 8, 13, 15, 21], room temperature at 25°C [8, 13, 14, 21, 57], and acceler-
ated conditions varying between 35 and 40°C [8, 9, 11, 20, 27]. Particle size, PDI,
and zeta potential are usually followed during the storage time, and the physical
integrity of the dispersions is observed for up to 6 months. This good stability is
expected for these nanosystems considering their colloidal nature and the absolute
zeta potential values which are estimated varying between 15 and 40 mV.
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3.2.5 Release behavior
Table 1 summarizes the reported work conditions used to carry out the release
tests. No matter what type of particles, dialysis is the most used technique to
investigate their drug release behaviors, usually at 37°C in PBS media of pH 6.8 or
7.4. Comparisons of drug release data is risked because significant changes in the
delivery behaviors are caused by the type of particle and its composition, the nature
of the active molecule, and the work conditions associated with the release test,
however, worth the risk for gaining a general view.
Thus, even though the mathematical modeling of the drug release data reported
for the carriers of interest predicts Higuchi and Korsmeyer-Peppas kinetics, differ-
ences in the drug release patterns of polymeric, lipid, and hybrid particles are
evidenced (Figure 4). In this way, biphasic release behaviors seem to be character-
istic when nanoprecipitated polymeric particles, whether nanospheres or
nanocapsules, are investigated. In these cases, the equilibrium is reached after 20 or
30 h of begun the study, and drug concentrations varying from 60 to 80% are
released. Paclitaxel-loaded PLGA nanoparticles are the exception; in this case, a
slow and constant drug release process occurs delivering hardly 40% of the active
encapsulated after 60 h. Perhaps, the low entrapment efficiency of this molecule
into the carriers makes the diffusion phenomena related to the active molecule
delivery (37–70%) difficult.
On its part, the drug release patterns observed when lipid nanoparticles are
tested seem to be those where the active molecule has faster delivery (before the
Figure 3.
General behaviors of particle size (A), polydispersity index (B), drug entrapment efficiency (C), and drug
loading (D) for polymeric nanospheres (PNS), polymeric nanocapsules (PNC), solid lipid nanoparticles
(SLN), nanostructured lipid carriers (NLC), and hybrid nanoparticles (HNP).
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Nanoparticle Drug release study Reference
Method Medium Stirring Operating
conditions
Polymeric nanoparticles
PNC Directly added at the
release medium
pH 6.8 PBS Magnetic 25 rpm 37 2°C [19]
PNS USP Apparatus I pH 6.8 PBS Mechanical
100 rpm
37 2°C [33]
PNS Franz diffusion cells
(sheep nasal mucosa)
pH 6.4 PBS 100 rpm 37 0.5°C [57]
PNS Dialysis 12–14 kDa pH 7.4 PBS Mechanical
100 rpm
37 1°C [29]
PNS Directly added at the
release medium/
centrifugation
pH 7.4 PBS with
0.5% w/v
polysorbate
Eppendorf
thermomixer,
gentle stirring
37°C [16]
PNS Dialysis pH 7.4 PBS Magnetic
100 rpm
37°C [17]
PNS Franz diffusion cells
(dialysis 12–14 kDa)
pH 7.5 PBS Magnetic
600 rpm
32°C [18]
PNS Dialysis 14 kDa pH 7.4 PBS Shaker 100 rpm 37 2°C [26]
PNS Dialysis 10 kDa pH 7.4 PBS 100 shakes/min 37°C [27]
Lipid nanoparticles
SLN/NLC Directly added at the
release medium
1% wt SDS
solution
Shaker 60
strokes/min
37 2°C [15]
SLN/NLC Directly added at the
release medium/
centrifugation
0.2% wt SDS
solution
Shaker 60
strokes/min
37 2°C [28]
SLN Dialysis 50 kDa pH 7.4 PBS Shaker 50 rpm 37 2°C [24]
SLN Dialysis 14 kDa pH 7.4 PBS Shaker 100 rpm 37 2°C [26]
SLN Dialysis/USP
Apparatus II
pH 7.4 PBS Mechanical
100 rpm
37 2°C [13]
Hybrid nanoparticles
HNP Dialysis 3.5 kDa pH 7.4 PBS Gentle stirring 37 °C [33]
HNP Dialysis 12–14 kDa pH 6.8 PBS
(0.1 M)
Shaker 90 rpm 37  2°C [12]
HNP Dialysis 10–12 kDa pH 7.4. PBS with
0.1% (v/v) DMF
150 rpm 37  0.5°C [9]
HNP Dialysis 12 kDa pH 7.4 PBS Shaker 100 rpm 37  2°C [4]
HNP Dialysis 3.5 kDa pH 7.4 PBS 100 rpm 37 °C [6]
HNP Dialysis 8–14 kDa pH 7.4 PBS with
0.5% polysorbate
80
100 rpm 37°C [56]
HNP Dialysis 10 kDa pH 7.4; 6.8 and
5.5 PBS
100 rpm 37  1°C [8]
HNP Dialysis 12 kDa pH 7.4 PBS nr. 37 °C [14]
HNP Dialysis 100 kDa pH 6.8 PBS,
water, and HCl
0.1 M solution
nr. nr. [32]
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first 20 h) and, at a rate, higher than 80%. Nimodipine reached delivered concen-
trations near 100% at 10 h, and other molecules such as tetracaine and nevirapine
exhibit biphasic behaviors reaching drug deliveries higher than 80% at 25 h. NLC
Nanoparticle Drug release study Reference
Method Medium Stirring Operating
conditions
HNP Dialysis 12 kDa pH 7.4 PBS Magnetic
200 rpm
37  2°C [5]
HNP Dialysis 10 kDa pH 7.4 PBS nr. 37 °C [23]
HNP Dialysis 10–12 kDa PBS with pH 7.4
FBS (10%)
100 rpm 37°C [11]
PNS: polymeric nanospheres; PNC: polymeric nanocapsules; SLN: solid lipid nanoparticles; NLC: nanostructured
lipid carriers; HNP: hybrid nanoparticles; SDS: sodium dodecyl sulfate; DMF: dimethylformamide; PBS: phosphate
buffer solution; FBS: fetal bovine serum; nr.: non-reported data.
Table 1.
Summary of the work conditions used to investigate the drug release behavior of nanoparticles prepared by the
nanoprecipitation technique.
Figure 4.
Drug release behaviors for polymeric nanospheres (A), polymeric nanocapsules (B), solid lipid nanoparticles (C),
nanostructured lipid carriers (D), hybrid nanoparticles obtained from the mixture of polymers and lipids (E),
and hybrid nanoparticles obtained from chemically modified polymers with lipids (F) (PTX: paclitaxel; PVA:
polyvinyl alcohol; ATE: atenolol; F: formulation; DEX: dexamethasone; CAP: cellulose acetate phthalate; HSA:
human serum albumin; DZP: diazepam; TETR: tetracaine; F68: Pluronic 68; FLU: fluticasone propionate; KET:
ketamine; SH: shellac; DOX: doxorubicin; P85: Pluronic 85; DICLO: diclofenac; MGL: Miglyol 810; LAB:
labrafac; FEN: fenofibrate, NEV: nevirapine; NIM: nimodipine; P80: polysorbate 80; CLOB: clobetasol
propionate; CCT: caprylic/capric triglycerides; EFA: efavirenz; SA: stearylamine, SL: soy lecithin; Lec: lecithin;
METH: methotrexate; PSO: psoralen; TPGS: tocopheryl polyethylene glycol succinate; QUE: quercetin; Tf:
transferrin; SOR: sorafenib; LIN: linezolid; DTX: docetaxel; MPA: mycophenolate; TL: triptolide).
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appear to be more efficient than SLN during the release process. The highest
amounts of active molecule that could be encapsulated because of the oil compo-
nent in the particle structure might have influence. Once again, there are exceptions
to the general behavior. In this way, slow-release processes as in the case of
clobetasol and fenofibrate, lead to less than 40% of active molecule released even at
100 h. It is important to keep in mind that fenofibrate has a high logP value (5.2)
and that clobetasol propionate was the starting material to prepare the
nanoparticles. Thus, a high affinity of the active molecules for the lipid matrix of
the particle would difficult its delivery process.
Hybrid nanoparticles, irrespective of whether the particles are obtained from the
mixture of polymers and lipids (Figure 4E) or by using chemically modified poly-
mers with lipids (Figure 4F), characterize by a very slow release of the active
molecule where, for example, some carriers deliver above 90% of the drug after
50 h of started the test. It should be noted that in this case, the data are reported
twice the set time for the other carriers. For some active molecules such as metho-
trexate, N-acetylcysteine, psoralen, quercetin, and paclitaxel, the prolonged drug
release could be related to the uniform distribution presumed for the drug into the
matrix and the core-shell structure of the particle, which difficult the diffusion of
the drug toward the release medium [9]. Likewise, the hydrolysis and erosion
processes of the polymeric core could be hindered by the lipid layer surrounding the
polymeric core [34] or, perhaps, the hydrophobic interactions of the active mole-
cule with the polymer might result of relevance for the drug release [5]. These
effects offset, for example, the favorable solubility gained because of the precipita-
tion of amorphous active during the preparation of the particles, which is expected
to facilitate the drug delivery [9].
4. In vivo performance of carriers prepared by nanoprecipitation
Drug delivery systems such as the polymeric, lipid, and hybrid nanoparticles
have been promoted for use in therapeutics as an interesting approach to facilitate
uptake of drugs at the desired site of action, particularly when free drugs might give
rise to significant off-site toxicities or characterize by poor bioavailability because
of their molecular and physicochemical properties. Accordingly, knowing the bio-
availability behaviors, including the pharmacokinetic parameters and the
biodistribution of the carriers obtained via the nanoprecipitation technique, as well
as the stability of the carriers in biological fluids and their cellular uptake, result of
paramount importance to investigate their applicability in pharmaceutics.
Considering that submicron sizes for most particles prepared by nanopreci-
pitation range between 200 and 300 nm, which are larger than pores between
endothelial cells, it is expected that, in the absence of specific affinity for receptors,
their distribution is limited to the vascular space. Nevertheless, for example, larger
endothelial pores such as the fenestrations in the liver and the spleen might lead to
the uptake of the particles by these tissues via bulk fluid flow. Once in the blood-
stream, particles are coated with a layer of plasma proteins (opsonization or protein
corona formation) facilitating their elimination by immune cells. Besides, dynamic
interactions between nanoparticles and blood cells, e.g., erythrocytes, platelets, and
leukocytes, could occur. Then, the carriers are entrapped in the microvasculature
and clearing compartments of the reticuloendothelial system like the liver, the
spleen, the bone marrow, and the lung, via phagocytic uptake by cells accessible
from the vascular space such us the hepatic Kupffer cells. This allows the elimina-
tion of the particles from the organism via the bile ducts into the feces or in the
urine [70].
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To provide a therapeutic response, nanoparticles must overcome these physio-
logical clearance mechanisms and distributional barriers. The objective is to guar-
antee a high mean residence time for the carriers in the systemic circulation while
their drug release delivery is modulated. Some alternatives in this way include the
development of particles exhibiting sizes less than 100 nm or a positive surface
charge. Stealth particles by using nonionic polymers or mimic the outer surface of
blood cells by locating mixtures of phospholipids, cholesterol, sphingomyelin, and
ganglioside molecules on the particle surface have also been proposed, and the
modification of the particle surface with specific ligands appears as the best strategy
for the target delivery of active substances up to now [61, 70].
Regarding the carriers prepared by nanoprecipitation, among the reported
developments of particles that could theoretically allow them a better in vivo per-
formance are: (i) particle sizes lesser than 100 nm for polymeric nanospheres
[25, 26, 34], solid lipid nanoparticles [71], and hybrid nanoparticles [7, 34, 56], (ii)
positively charged polymeric nanospheres by using chitosan [72] and Eudragit® RL
100 [18] as polymers or positively charged hybrid nanoparticles prepared from
lipids as the stearylamine [5], (iii) stealth polymeric nanospheres [17, 27] and
stealth hybrid particles [4–8], and (iv) targeted cancer hybrid particles [7, 59].
4.1 Pharmacokinetic parameters
An approach to the pharmacokinetic aspects of the particles prepared via
nanoprecipitation is made from the reported studies where carrier dispersions were
administered by the intravenous, oral, and intranasal routes to animal models as
Sprague-Dawley rats, Wistar rats, and BALB/c mice (Table 2). First, the slow-
release patterns previously discussed appear to be maintained in the in vivo behav-
ior, i.e., nanoparticles extend in some way the drug delivery regardless of the
administration route and the carrier properties. Thus, mean residence times (MRT)
in the systemic circulation between 1.2 and 20 folds higher than that for the free
drug and elimination half-lives between 5 and 10 folds higher than free drug are
achieved. Likewise, larger values of area under curve (AUC) are reported which,
provided that the amount of drug that is released allows the therapeutic dose
required, are attractive for treating chronic diseases where less frequent dosing
regimens are convenient.
A general view depending on the administration route (Figure 5, where solid
and dashed lines correspond to carriers and free-drug plasma profiles, respectively)
shows that polymeric particles orally administered increase the Tmax, Cmax, and
AUC0-t values compared with free drugs administered in suspension or, as in the
case of lipid nanoparticles, with an intravenously administered solution of the drug.
The slow drug release behavior characteristic of lipid particles, where Tmax is
abruptly reached after 20 h of administration is interesting. On the other hand,
although Tmax, Cmax and, AUC are increased when using hybrid particles, it must be
noted that drug could be rapidly or slowly delivered to the serum which might be
related to the location of the active molecule into the particle. For example, if the
active molecule is located at the lipid shell surrounding the polymeric core, the drug
might be easily released; on the contrary, if the active molecule locates at the
polymeric core, more extended drug release behaviors could be obtained. Zhu et al.
[4] and Godara et al. [5] demonstrate the usefulness of the lipid layer covering the
polymeric core in the hybrid particles to prolong the circulation time of the parti-
cles. Probably, the lipid shell restricts the plasma protein adsorption reducing the
opsonization phenomena. Moreover, the modifications of the particle with cholate
enhance the drug absorption by the oral route. Likewise, developments as that of
mycophenolate particles containing quercetin, where the antioxidant activity of
12
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Active molecule—
carrier
Active ingredient Route of
administration
Animal model Equivalent dose of
active molecule
Tmax
(h)
Cmax AUC0-t MRT
(h)
t 1/2
(h)
Reference
Polymeric nanoparticles
PNS Itraconazole Parenteral Sprague-Dawley rats 5 mg/kg 7.7 nr. 1.2 μg h/mL 12.4 nr. [22]
PNS (PEG-PLGA) Ketamine Parenteral Male C57BL/6 J mice 1 mg/kg nr. 20.1 μg/mL 88.6 μg h/mL nr. 103.1 [27]
PNS (PEG-PLGA:SH) nr. 19.6 μg/mL 86.8 μg h/mL nr. 79.7
PNS Paclitaxel Oral Wistar rats 10 mg/kg 6.0 3.6–4.2 μg/mL nr. nr. nr. [5]
PNS Diazepam Intranasal Sprague-Dawley rats 0.2–0.25 mg/kg 2.0 2.4%/g 13.9% h/g nr. nr. [57]
Lipid nanoparticles
SLN (P80) Nevirapine Parenteral Wistar rats 20 mg/kg 4.0 9.3 μg/g 2.9 μg h/g 17.4 27.6 [13]
SLN 4.0 5.8 μg/g 1.1 μg h/g 8.6 7.2
SLN Amphotericin B Oral Sprague-Dawley rats 3.6 mg/kg 24.0 1.1 μg/mL 27.9 μg h/mL nr. 15.9 [21]
Hybrid nanoparticles
HNP Doxorubicin Parenteral Male Sprague-
Dawley rats
20 mg/kg nr. 17.5 μg/mL 62.9 μg h/mL 9.5 6.4 [4]
HNP (P85) nr. 17.8 μg/mL 75.4 μg h/mL 10.82 7.1
HNP (Tf-P85) nr. 19.9 μg/mL 107.1 μg h/mL 11.43 8.0
HNP Docetaxel Parenteral BALB/c female mice 10 mg/kg nr. 8.0 μg/mL 198.5 μg h/mL 34.9 25.7 [8]
HNP Mycophenolate Oral Sprague-Dawley rats 25 mg/kg equivalent
to MPA and QC
nr. 1.2 μg/mL 27.4 μg h/mL 34.0 24.1 [14]
HNP Mycophenolate + quercetin nr. 1.2 μg/mL 35.9 μg h/mL 46.0 28.4
HNP Quercetin Oral Sprague-Dawley rats 25 mg/kg 1.0 8.8 μg/mL 33.3 μg h/mL nr. 3.4 [32]
HNP Paclitaxel Oral Wistar rats 10 mg/kg 6.0 6.8–7.6 μg/mL nr. nr. nr. [5]
PNS: polymeric nanospheres; SLN: solid lipid nanoparticles; NLC: nanostructured lipid carriers; HNP: hybrid nanoparticles; Tf: transferrin; P85: Pluronic 85; Tmax: time taken to reach peak plasma concentration; t 1/2:
half-life; Cmax: maximum concentration; AUC 0-t: area under the curve of a plasma concentration versus time profile; MRT: mean residence time; P80: polysorbate 80; PEG: poly(ethylene glycol), PLGA: poly (D,L-lactic-
coglycolic acid), SH: shellac, nr.: non-reported data.
Table 2.
Summary of the pharmacokinetic parameters reported in research works on nanoparticles prepared by the nanoprecipitation technique.
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quercetin inhibits the mycophenolate metabolism through cytochrome P450, are
highlighted. This, together with the slow-release pattern of the particles, improves
in a significant way the in vivo performance of the hybrid nanoparticles [14].
Concerning the administration of carriers by the intravenous route, pharmaco-
kinetic advantages were also evidenced compared to the free drug administration.
As reported by Bian et al. [22] and Han et al. [27], even if a fraction of the polymeric
nanoparticles are quickly removed by the reticuloendothelial system during the first
4 h after the administration, the remaining particles into the systemic circulation
allow a sustained drug delivery for more than 20 h achieving AUC0-t values from 2
to 10 times higher than free drug. As intended, pegylation of polymeric
nanoparticles extends the elimination half-life by 100 h and increases in 84% the
AUC regarding the free drug [27]. With respect to lipid carriers, Lahkar et al. [13]
evidence a significant increase of their AUC0-t which could remain in the blood
circulation four times more than the free drug. Moreover, modifications to the
particle surface providing some hydrophilicity with polysorbate 80 result in an
MRT eight times higher than that of the free drug. Regarding the hybrid
nanoparticles, Zhu et al. [4] provide evidence on their extended drug delivery
pattern that is improved as modifications on the particle surface are introduced.
Thus, plasma circulation of the particles and their corresponding AUC0-t could be
prolonged up to six and seven times, respectively, compared with that for the free
drug. Jadon and Sharma [8] illustrate results in the same direction where drug
Figure 5.
General behaviors of plasma concentration reported for polymeric nanoparticles (A and B), lipid nanoparticles
(C and D), and hybrid nanoparticles (E and F). Oral administration (A, C, and E); intravenous
administration (B, D, and F) (PTX: paclitaxel; FD: free drug; F68: Pluronic 68; HSA: human serum albumin;
KET: ketamine; SH: shellac; ITZ: itraconazole; NEV: nevirapine; AmphB: amphotericin B; P80: polysorbate
80; SA: stearylamine; SL: soy lecithin; P: PLGA; MPA: mycophenolate; PVA: polyvinyl alcohol; QUE:
quercetin; cHNP: cholate-modified hybrid nanoparticle; DOX: doxorubicin; DTX: docetaxel; P85: Pluronic 85;
tf: transferrin).
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delivery from the hybrid particles continues to be detected 72 h after the adminis-
tration with AUC0-t values around 3.6 times higher than free drug.
4.2 Biodistribution
Figure 6 shows an overview of the organ distribution patterns of the carriers
under study as an approximation of their in vivo transport and metabolism pro-
cesses depending on the route of administration. Perhaps, these behaviors would
better correspond to the carried drug since the concentration of the active molecule
in the tissues of interest is the measure commonly used to follow the particles in this
kind of experiments. Once again, it is the intention to illustrate general behaviors;
therefore, the punctual analyses on the particular work conditions used by each
research team such as the animal models, the sampling times, and the way as the
samples were analyzed are not considered. Thus, caution must be taken to do
statements that lead to misinterpretations.
As can be seen in Figure 6, after 8 h of oral administration of both lipid and
hybrid carriers, the liver, the spleen, and the kidney appear as the organs where
lipid and hybrid particles are located. This could be attributed to the important role
of the liver in the clearance of the particles and the blood filtration function of
spleen within the immune system which might also remove the particles of the
bloodstream. On its part, drug concentration in the kidney could mean the normal
transit of the carrier because of the systemic circulation and the high irrigation of
this organ. Nonetheless, the elimination process of intact carriers would also be
happening.
On the other hand, as expected, the brain accumulates substantial amounts of
lipid nanoparticles administered via intranasal because of the closeness of this organ
to the nasal mucosa and its high blood perfusion. This behavior should be harnessed
to improve therapies targeted to the brain as those for the treatment of diseases of
the central nervous system. Likewise, particles intended for lung cancer therapies,
prepared from a hyaluronan-modified polymer, and administered via
Figure 6.
General behavior of biodistribution for polymer, lipid, and hybrid nanoparticles after administration by oral,
intranasal, intrapulmonary, and intravenous routes. Administration by intravenous, intranasal and oral
routes (black-filled symbols) and by intrapulmonary route (crossed symbols) (KET: ketamine; NEV:
nevirapine; DTX: docetaxel; DZP: diazepam; AmphB: amphotericin B; MPA: mycophenolate; QUE:
quercetin).
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intrapulmonary route, directly locate on lung up to 24 h [59]. This finding confirms
the ability of hyaluronan to be recognized by cancer lung receptors allowing the
particle concentration in this tissue and consequently, avoiding the waste of active
substance in other organs.
Regarding the intravenous administration, it seems that after 24 h, polymeric
nanoparticles mainly locate at the lung, liver, and brain; lipid particles are distrib-
uted in blood, liver, kidney, and spleen; and hybrid particles accumulate in the
liver. However, it should be noted that regardless of the kind of particle and
compared with the oral and intranasal administration, when carriers are adminis-
tered by intravenous route, drug is found in low levels in all the investigated organs.
In addition, after extended periods (e.g., 120 h), particles are more homogeneously
distributed among the investigated tissues [27]. This is a natural consequence of the
systemic circulation and the irrigation of the different organs. Besides, as previously
mentioned, there is a high probability that the concentration of carriers on the liver
occurs due to the ability of the hepatic Kupffer cells to phagocyte them. Likewise,
the phagocytic activity of the alveolar macrophages could explain why high con-
centrations of the drug are found in the lung. In addition, to find carriers or active
molecules in the stomach might also be possible considering that the pH of this
tissue could favor the retention of active molecules exhibiting a basic nature.
It is important to highlight the efficacy of targeted carriers to reach the intended
tissues. As it has been evidenced by Jeannot et al. [59], working with polymeric
nanoparticles, the functionalization of the polymer with polysaccharide
hyaluronan, known for its affinity toward certain cancer cells receptors, allows high
concentrations of particles on the lung offering an interesting alternative for the
lung cancer treatment. In the same direction, Dehaini et al. [7] demonstrate the
ability of docetaxel-loaded hybrid nanoparticles functionalized with folate to reach
cancerous tumors.
4.3 Stability in biological fluids
Knowing if nanoparticles aggregate after their in vivo administration is of crucial
importance for their application as drug delivery systems. To this end, the colloidal
stability of the particulate systems dispersed in biological fluids has been investi-
gated by monitoring variables such as the particle size and the drug encapsulation.
Thus, Lazzari et al. [73] demonstrated that polymeric nanospheres prepared by
flash nanoprecipitation from PMMA were stable up to 60 h in synthetic saliva,
gastric juice, intestinal fluid, and lysosomal fluid while PLA nanoparticles aggregate
in gastric juice. Likewise, Dehaini et al. [7] report the aggregation of PLGA
nanoparticles in fetal bovine serum (FBS). On the other hand, polymeric
nanocapsules coated with brush layers of an oligo ethylene glycol derived methac-
rylate polymer exhibit major stability in human serum albumin solution, FBS, and
human blood plasma, that those non-coated [74]. This evidences the usefulness of
designing stealth nanoparticles as a strategy to prevent the particle aggregate for-
mation in blood avoiding their rapid removal from the systemic circulation by the
immune system. Regarding SLN, Liu et al. [26] verified their colloidal stability in
FBS reporting increases in particle size of approximately 50%, although encapsula-
tion efficiency does not vary. Chaudhari et al. [21] delved into the stability of SLN in
simulated gastric fluid confirming that after 2 h, amphotericin B remains encapsu-
lated favoring its stability. With respect to hybrid nanoparticles, contradictory
results of aggregation [23] and non-aggregation [7] have been reported when the
particle dispersions are mixed with FBS. This can be attributed to the experimental
conditions used. In the first case, aggregation is reported after 2 days of storage of
the samples at 37°C; in the second one, aggregation was investigated immediately
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Nanoparticle Assay Experimental conditions General results Reference
Cellular model Tracer
molecule
concentration
Interaction—
cellular model
(some work
conditions)
Technique of analysis
PNS CD44
expression
levels
Human H322, H358, and A549
NSCLC cell lines
8 μg/mL 30 min at 37 C Flow cytometry
FITC
Dose-dependent binding of NP 30 nm
and NP 300 nm, was observed in the
three cell lines, with a higher intensity
for A549 cells compared with H322 and
H358 cells.
[59]
HNP Cellular uptake The MDA-MB-231 breast cancer
cells; human prostate cancer
PC3 cells
10, 300, and
500 μg/mL
24 h CLSM High internalization of the HNP in the
cells at the highest concentrations.
[9]
HNP Cellular uptake A549 human lung
adenocarcinoma cells
20 μg/mL 24 h Flow cytometry Functionalization of HNP plays a key
role in the uptake of drugs in in vitro
lung cancer cells.
[6]
HNP Cellular uptake
Qualitative
study
Human breast adenocarcinoma
MDA-MB-231 cells
1 μg/mL 12 h CLSM The improved cell uptake efficiency of
HNP is attributed by cytosolic delivery
of the drug.
[8]
HNP Cellular uptake
Quantitative
study
Human breast adenocarcinoma
MDA-MB-231 cells
Equivalent to
10, 20, 30, and
40 μg/mL
24 h CLSM HNP exhibit improved cellular uptake
efficiency (45–48%) compared with
free drug (37–39%).
[8]
HNP Cellular uptake
analysis
MCF-7 human breast cancer cell 1 μg/mL 2 h Differential interference
contrast microscopy
High internalization of HNP inside the
cells after 2 h of incubation with
respect to reference nanoparticles.
[14]
HNP Cellular uptake Caco-2 cells 25 μg/mL 0.5–2 h Protein quantification:
BCA protein assay kit
Drug quantification:
HPLC
HNP exhibited improved cellular
uptake of quercetin relative to its free
form, showing a time-dependent
uptake accumulation.
[32]
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Nanoparticle Assay Experimental conditions General results Reference
Cellular model Tracer
molecule
concentration
Interaction—
cellular model
(some work
conditions)
Technique of analysis
HNP Internalization
into osteoblasts
MC3T3-E1 osteoblasts 2, 4, and
8 μg/mL
6 h at 37°C CLSM HNP were more effective in reducing
the intracellular MRSA counts than the
free linezolid.
[23]
HNP Cellular
internalization
Prostate cancer cells (PC3-
MM2) and human breast cancer
cells (MDA-MB-231)
100300
μg/mL
3 min at 37°C CLSM
FITC
Cellular uptake ability depends on
particle concentration.
[11]
PNS: polymeric nanospheres; HNP: hybrid nanoparticles; NP: nanoparticle; MTX: methotrexate; FITC: fluorescein isothiocyanate; HPLC: high-performance liquid chromatography; CLSM: confocal laser
scanning microscope; MRSA: methicillin-resistant Staphylococcus aureus; nr.: non-reported data.
Table 3.
Summary of experimental conditions and general results reported in research works on cellular uptake of nanoparticles prepared by the nanoprecipitation technique.
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the particle dispersions were diluted. On the other hand, when the stability of
hybrid particles was tested in human plasma, interactions of particle and serum
proteins were evidenced which increased the carrier size. But what is more inter-
esting is that those interactions seem to be related to the type of stabilizing agent
used. As reported by Godara et al. [5], by using PVA or stearylamine as stabilizing
agents, particle sizes increased 15% that contrast with an increase of 50% when
particles were stabilized with human serum albumin. Maybe, the protein layer
covering the particle surfaces promote their interaction with the serum proteins.
4.4 Cellular uptake
Regarding cellular uptake, Table 3 reports the experimental conditions and
general results. Indeed, researches on this regard have been mostly carried out for
the hybrid nanoparticles by using human cancer cells taken in their majority from
the breast. Nevertheless, some research works have also investigated on prostate
and lung cancer cells. Other used cell lines include Caco-2 and MC3T3-E1 osteo-
blasts. In general terms, the analyses by flow cytometry and confocal laser scanning
microscopy reveal that the functionalization of the hybrid particles favors the
in vitro cellular uptake when compared to the free drugs and the pattern of cellular
uptake correlates with the carrier drug loading.
On the other hand, the ability of nanoparticles to penetrate the different physio-
logical barriers and reside in the target tissues has also been demonstrated. For exam-
ple, SLN could provide efficient in vivo skin permeation [26], polymeric nanoparticles
might penetrate mucus also exhibiting mucoadhesive behavior [16], and hybrid
nanoparticles would cross the enterocyte walls [32] or reach bone tissue [23].
5. Safety and efficacy of carriers prepared by nanoprecipitation
5.1 Safety
A revision of the starting materials used to prepare particles via nanopreci-
pitation shows that the polymers and lipids present in the different recipes are
recognized as safe considering their biocompatibility. Likewise, most organic sol-
vents are classified as with low toxic potential according to ICH [75]. In the cases
where acetonitrile, dichloromethane, tetrahydrofuran, dimethylformamide, and
even methanol are used as solvents, the obtained particles should meet the specific
requirements of limited concentrations of residual solvent because of their inherent
toxicity. Traces of organic solvents would remain in the nanoparticle dispersions
after the stage of solvent removal during their preparation. For example, up to
2300 ppm of tetrahydrofuran can be detected in lipid nanoparticles, which exceed
the limit of 720 ppm established by the ICH [75]. However, as shown in Table 4,
the safety tests including hematological studies on mice [27], hemolysis assays on
human blood [8] or with erythrocytes [5], MTT assay on alveolar epithelial cells
[34] or osteoblasts [23], cell viability on cancer cells [9, 11], and histological exam-
ination of mice [56], evidence concerns on the safety of that particles, and in
general, neither of the particles were prepared via nanoprecipitation. Moreover,
nanoparticles reduce the toxicity of the active molecules [8, 57].
5.2 Efficacy
One of the promising applications of nanoparticles, including those obtained by
nanoprecipitation, is the therapy against cancer. As shown in Table 5, hybrid
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Nanoparticle Experimental conditions for toxicity testing General results Reference
Cellular/animal model Assay Drug
concentration
or dosage used
Time of
interaction—
cellular model
(h)
Technique of
analysis
Polymeric nanoparticles
PNS Vero cell line (green monkey kidney
epithelial cells)
MTT assay 3.12–100 μg/mL 24 h ELISA microplate
reader
Nanoparticles reduce cytotoxicity of the
active molecule.
[57]
PNS Normal human keratinocytes MTT assay 0.05 and 0.5 mg/
mL
48 h Microplate reader No cytotoxic effect was detected after
exposure of the NHK for 24 and 48 h to the
nanoparticles.
[18]
PNS Normal human keratinocytes (H2DCFDA)
assay
0.5 mg/mL 1 h FITC fluorescence The nanoparticles have no oxidative stress
induction potential.
[18]
PNS Male C57BL/6 J mice Hematological
studies
1 mg/kg 5 days Hematology
analyzer
All hematological parameters assessed at
study remained in the normal range for
mice.
[27]
Lipid nanoparticles
SLN Sprague-Dawley rats Renal toxicity
assessment
3.6 mg/kg 72 h UV-visible Freeze-dried nanoparticles are considered
as a safe oral alternative.
[21]
SLN Wistar rats (OECD)
guidelines, 423
5–2000 mg/kg 14 days LD50 by Karber
method
None of the animals showed any sign of
toxicity. The lethal dose (LD50) of KB is
higher than 2000 mg/kg.
[13]
SLN/PNS BALB/c 3T3 MTT assay 50–200 μM 24 h Microplate reader A moderate effect on cell viability, no
obvious changes were found.
[26]
Hybrid nanoparticles
HNP Normal L929 alveolar epithelial cells MTT assay 0.1–30 mg/mL 48 h Spectrophotometric No significant cytotoxicity against normal
alveolar cells.
[34]
20 Na
n
o-
a
n
d
M
icro-E
n
ca
p
su
la
tion
-
T
ech
n
iqu
es
a
n
d
A
p
p
lica
tion
s
Nanoparticle Experimental conditions for toxicity testing General results Reference
Cellular/animal model Assay Drug
concentration
or dosage used
Time of
interaction—
cellular model
(h)
Technique of
analysis
HNP MDA-MB-231 breast cancer cells;
human prostate cancer PC3 cells;
colon cancer HT29 cells
Cell viability 50 to 300 μg/mL Over night Fluorescence
intensity
No cytotoxic effects were observed for the
particles tested.
[9]
HNP BALB/c female mice Side effects on
vital organs
3 mg/kg 21 days Histological
examination
No significant toxicity to the heart, liver,
spleen, lung, or kidney.
[56]
HNP Whole human blood (from a healthy
person)
Hemolysis
assay
1 μL of suitably
diluted free DTX
and HNP
0.5 h Spectrophotometric The hemolysis of nanoparticle formulation
was lesser than free drug.
[8]
HNP Sprague-Dawley rats In vivo
toxicity
25 mg/kg 30 days Spectrophotometric Concentration of hepatotoxicity
biomarkers (ALT and AST) was
insignificant as compared to control.
[14]
HNP MC3T3-E1 osteoblasts MTT assay 0.5–40 μg/mL 16 h Microplate reader All groups showed minimum cytotoxicity
against osteoblasts.
[23]
HNP Erythrocytes Hemolysis
assay
0.7 mg/mL 1 h Spectrophotometric The average percentage hemolysis rate of
nanoparticles was found between 7 and
16%.
[5]
HNP Prostate cancer cells (PC3-MM2)
and human breast cancer cells
(MDA-MB-231)
In vitro
cytotoxicity
studies
25, 50, 100, 150,
200, and 300 μg/
mL
48 h Measure the
luminescence
No cytotoxic effects were observed. [11]
PNS: polymeric nanospheres; SLN: solid lipid nanoparticles; HNP: hybrid nanoparticles; MTT: 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide; OECD: Organisation for Economic Co-
operation and Development; KB: kokum butter; H2DCFDA: 6-carboxy-20,70-dichlorodihydrofluorescein diacetate; NHK: normal human keratinocytes; FITC: fluorescein isothiocyanate; PLGA: poly(D,L-
lactide-co-glycolide); ALT: alanine transaminase; AST: aspartate transaminase; DTX: docetaxel; nr.: non-reported data.
Table 4.
Summary of experimental conditions and general results reported in research works on safety testing of nanoparticles prepared by the nanoprecipitation technique.
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Nanoparticle Experimental conditions for efficacy testing General results Reference
Assay Cellular/animal model Drug concentration Time of
interaction
—cellular
model
Technique of analysis
Polymeric nanoparticles
PNS (Brazilian red
propolis extract)
Antioxidant
activity by using
DPPH method
— 80 μg/mL 30 min Spectrophotometry UV The PNS displayed good antioxidant
activity with inhibition values
higher than 75%.
[36]
Antileishmanial
in vitro assay
L. (V.) braziliensis
culture
5–100 μg/mL 24 h Inverted microscopy Nanoparticles containing between
30 and 40% of EEP maintained
antileishmanial activity like the EEP
in its original form.
PNS (fluticasone
propionate)
Mucus mobility
by multiple
particle tracking
Human cervicovaginal
mucus
0.2–0.5 μL
(nanosuspension)
30 min Fluorescent microscopy Particles exhibit rapid mucus
penetration and mucoadhesive
behavior.
[16]
Anti-
inflammatory
action
Lewi rats 0.1 mg of FP/kg 24 h Total and differential cell
counts on an automated cell
counter.
Inhibition of bronchoalveolar lavage
fluid (BAL) lavage neutrophils
between 50 and 70% in 24 h.
Duration of
residence in
mouse lung
CF-1 mouse 10 μg of FP per
animal
24 h HPLC/MS Upon deposition onto respiratory
tissue, solution formulations or non-
encapsulated drugs are rapidly
removed through absorption into
systemic circulation compared with
nanoparticles.
Lipid nanoparticles
L-βCD-C10
L-βCD-C10/DOPE-
PEG
L-βCD-C10/
stabilizer (nr.)
Complement
protein C3
activation
Polyclonal anti C3
antibody
Topical 75 min Immuno-electrophoretic L-βCD-C10/DOPE-PEG shows a
low level of complement C3
activation.
[71]
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Nanoparticle Experimental conditions for efficacy testing General results Reference
Assay Cellular/animal model Drug concentration Time of
interaction
—cellular
model
Technique of analysis
SLN/PNS
(tetracaine)
Franz diffusion
cell
Hairless abdominal full-
thickness skins of
Sprague-Dawley rats
Corresponding to
5 mg of tetracaine
72 h Spectrophotometry UV SLN provides an efficient in vitro
permeation and sustained
performance up to 72 h.
[26]
Tail-flick test Sprague-Dawley rats 0.25 mg/mL 4 h Response threshold (seconds
to withdraw the tail before
the thermal stimulus).
PNS exhibited prolonged
antinociceptive effect showing
efficiency until 3.5 h of study.
Paw pressure test Sprague-Dawley rats 0.25 mg/mL 8 h Response threshold (amount
of pressure supported by the
animal before removing the
paw).
The analgesic effects are maintained
for a longer period. Greater than
50% pain control was still found at 6
and 4 h for PNS and SLN,
respectively.
SLN (polymyxin B) Antimicrobial
evaluation
Strain of E. coli 6.6 μg/mL 2–18 h Turbidimetry Activity (% inhibition of growth) by
the plain drug and SLN were 52.7
and 56.7%, respectively.
[20]
SLN (amphotericin
B)
In vitro antifungal
efficacy
C. albicans 0.5–250 μg/mL 48 h Change in original blue color
of resazurin to pink.
Minimum inhibitory concentration
value of 7.812 μg/mL attributed to
controlled release of drug from the
nanoparticulate matrix.
[21]
Hybrid nanoparticles
HNP (docetaxel) Targeting studies KB cells 0.25 mg/mL 30 min Flow cytometry The targeted hybrid nanoparticles
were found much deeper within the
tumor and further away from the
vasculature.
[7]
In vivo tumor
treatment efficacy
Female nude mice 4 mg/kg 35 days Tumor width, length, and
size
Half of the mice were still alive at
64 days after tumor challenge. As an
indicator of global health, body
weights were monitored over the
course of the study.
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Nanoparticle Experimental conditions for efficacy testing General results Reference
Assay Cellular/animal model Drug concentration Time of
interaction
—cellular
model
Technique of analysis
HNP
(methotrexate)
Antiproliferation
assay
MDB-MB-231 breast
cancer and PC3 prostate
cancer cells
5, 10, 20, 50, 100,
150, and 200 μg/mL
72 h ATP-based cell viability kit MTX encapsulated in the HNP
preserve its anticancer activity.
[9]
HNP (doxorubicin) Cytotoxicity
evaluation
HL-60 cells and HL-60/
DOX. MTT assay
0.25, 0.5, 1, 2, 5, 10,
and 20 μg/mL
70 h Microplate reader The cytotoxicity activity of HNP
was superior to DOX solution. The
IC50 of HNP was lower than DOX
solution.
[4]
Tumor growth
inhibition
Male BALB/c mice 20 mg/kg 18 days Xenograft model The tumor growth inhibition was
(68.9–89.6%). The body weight of
the mice in any of HNP treatments
groups showed no obvious decrease
in comparison with untreated
groups.
HNP (paclitaxel) Cytotoxicity
(MTT assay)
A549 human lung
adenocarcinoma cells
0.5–10 mg/mL 48 h Microplate reader Drugs loaded HNP exhibited
marked cytotoxicity on cells in a
dose-dependent way and showed
higher cytotoxicity compared with
their free drug counterparts.
[6]
Synergistic effects A549 human lung
adenocarcinoma cells
0.5–10 mg/mL 48 h The results of cytotoxicity
were evaluated via the
Combination Index
The in vivo and in vitro results show
synergetic effect of the two drugs
incorporated in HNP against the
lung cancer.
In vivo antitumor
efficacy
BALB/c-nude mice 5 mg/kg of paclitaxel
and 3 mg/kg of
triptolide
18 days Tumor width, length, and
size
The inhibition of the in vivo tumor
growth was lesser than that of the
control group.
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Nanoparticle Experimental conditions for efficacy testing General results Reference
Assay Cellular/animal model Drug concentration Time of
interaction
—cellular
model
Technique of analysis
HNP (psoralen) Antitumor
efficacy
MCF-7 cells 3 mg/kg 21 days Changes in the tumor
volume and final tumor
weight
HNP show more efficient antitumor
effects respect to other
formulations.
[56]
HNP (docetaxel) Cytotoxicity
(MTT assay)
Human breast
adenocarcinoma MDA-
MB-231 cells
0.05, 0.1, 1, 10, and
20 μg/mL
24, 48, and
72 h
ELISA plate reader Cytotoxicity activity of HNP could
be attributed to lipid-mediated
cytosolic delivery of the drug which
is dose dependent.
[8]
Annexin V-FITC/
propidium iodide
apoptosis assay
MDA-MB-231 cells 10 μg/mL 24 h Flow cytometry Injured cells (including early
apoptosis, late apoptosis, and
necrotic cells) with HNP are greater
(87%) as compared with free drug
(51%).
Antitumor
efficiency
BALB/c female mice 10 mg/kg 3 weeks Tumor width, length and
size
The repeated dosing of HNP exhibit
less mortality (33%) than with free
drug.
HNP
(mycophenolate;
quercetin)
Annexin V
apoptosis assay
MCF-7 10, 20, 40, and
60 μg/mL
6 h CLSM Apoptosis indices of MPA-NP and
QC-NP are higher compared to
respective free drugs. Moreover, the
apoptosis index is significantly
higher when combination MPA-
NP + QC-NP is used.
[14]
Inosine-50-
monophosphate
dehydrogenase
(IMPDH) assay
MCF-7 1 μMMPA NP 24 h IMPDH assay kit Significantly higher enzyme
inhibition was observed in MPA-NP
than free MPA.
25 Na
n
op
recip
ita
tion
:A
p
p
lica
tion
s
for
E
n
tra
p
p
in
g
A
ctive
M
olecu
les
of
In
terest
in
P
h
a
rm
a
ceu
tics
D
O
I:h
ttp
://d
x
.d
oi.org/10
.5772
/in
tech
op
en
.93338
Nanoparticle Experimental conditions for efficacy testing General results Reference
Assay Cellular/animal model Drug concentration Time of
interaction
—cellular
model
Technique of analysis
In vivo antitumor
efficacy
Sprague-Dawley rats 25 mg/kg 30 days Tumor width, length, and
size
Combination therapy of MPA and
QC loaded LPN demonstrates
significant suppression of tumor
growth as compared to other
groups.
Cytotoxicity
(MTT assay)
MCF-7 human breast
cancer cell
10, 20, 40, and
60 μg/mL
nr. Optical density Combination treatment of
nanoparticles (MPA-NP + QC-NP)
shows significantly higher cytotoxic
effect compared with individual
nanopreparation (MPA-NP and QC-
NP).
HNP (quercetin) Cellular
internalization
Caco-2 cells 25 mg/kg 0.5 h CLSM Excellent affinity and permeability
to enterocytes allows HNP to be
efficiently transported.
[32]
Cytotoxic
evaluation on
P388 cells (MTT
assay)
Lymphoblastic leukemia
P388 cells
5, 10, and 20 μM 24 h Spectrophotometry UV HNP have higher cellular
approachability that accords well
with the cellular uptake by Caco-2
cells.
In vivo
antileukemic
effect
DBA/2 mice 25 mg/kg 21 days Automatic blood counter HNP can enhance the oral
bioavailability of QC.
HNP (paclitaxel) Plasma protein
binding study
Blood sample from a
healthy volunteer
0.7 mg/mL 2 h Bradford assay The protein binding of HNP was
found between 15.1 and 33.7%. The
interaction between the biological
environment and HNP can be
controlled by surfactant.
[5]
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Nanoparticle Experimental conditions for efficacy testing General results Reference
Assay Cellular/animal model Drug concentration Time of
interaction
—cellular
model
Technique of analysis
HNP (linezolid) Minimum
inhibitory
concentration
(MIC)
Strains of USA300-0114,
CDC-587, and RP-62A
500 μg/mL stock
solution in TSB, and
serially diluted for
the assay
24 h Broth dilution method
Microplate reader
The MIC50 and MIC90 values of
free linezolid were approximately
40–50% of the values of HNP.
[23]
Biofilm
microplate assay
S. aureus 32, 64, 128, 164, and
256 μg/mL
12 h Microplate reader HNP were more effective than free
linezolid for eradicating the MRSA
biofilm.
Biofilm
microplate assay
S. aureus 32, 64, 128, 164, and
256 μg/mL
12 h CLSM Extensive retention of the
nanoparticles in the biofilms even
after multiple buffer washing.
Drug’s levels in
animals’ bones
Sprague-Dawley rats 32, 64, 128, 164, and
256 μg/mL
24 h HPLC Bone linezolid levels from HNP
increase to over four-folds those of
the free drug.
HNP (sorafenib) Cell growth
inhibition assay
Prostate cancer cells
(PC3-MM2) and human
breast cancer cells
(MDA-MB-231)
5, 10, 20, 50, 100,
150, and 200 μg/mL
72 h Cell viability kit The inhibition of the tumor cell
growth was found to be time- and
dose dependent for drug solution as
well as HNP.
[11]
PNS: polymeric nanospheres; SLN: solid lipid nanoparticles; NLC: nanostructured lipid carriers; HNP: hybrid nanoparticles; CD: cyclodextrin; IC50: half-maximal inhibitory concentration; MPA:
mycophenolate; Nv: nevirapine; QC: quercetin; MIC: minimum inhibitory concentration; MTS: 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium; LRP:
luciferase reporter phage; CFU: colony-forming units; MTT: 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide; DOX: doxorubicin; MTX: methotrexate; HL-60: human leukemia cell line;
DPPH: 2,2-diphenyl-1-picryhydrazyl; EEP: ethanolic extract of propolis; NSCLCs: non-small cell lung cancers; NMRI: Naval Medical Research Institute; MS: mass spectrometer; HPLC: high-performance
liquid chromatography; CLSM: confocal laser scanning microscopy, nr.: non-reported data.
Table 5.
Summary of experimental conditions and general results reported in research works on efficacy testing of nanoparticles prepared by the nanoprecipitation technique.
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nanoparticles give good results in this sense. First, the incorporation of the active
molecules into the carriers preserve the anticancer activity [9] and nanoparticles
offer better performance compared with the free drug [4, 14, 56], in some cases
being dose dependent [6, 8, 11]. Besides, significant improvements in the in vivo
anticancer performance were achieved by the encapsulation of both an anticancer
molecule (mycophenolate) and an antioxidant agent (quercetin) into the same
hybrid nanoparticle, as quercetin prevents mycophenolate of its hepatic metabolism
via the oxygenase enzymes [14]. Moreover, it was demonstrated that the in vivo
tumor treatment in mice prolongs the life of the animals [7].
Taken advantage of the slow-release patterns that could be obtained with
nanoparticulated systems, the development of carriers exhibiting antimicrobial and
anesthetic activities are also of interest in research. Thus, the lowest values of
minimum inhibitory concentrations of SLN containing polymyxin B or
amphotericin B [20, 21] with respect to the free drugs contribute to support the
applicability of nanoparticles prepared by nanoprecipitation in this area. In line
with this, polymeric nanoparticles containing Brazilian red propolis extract have
also shown antileishmanial activity [36], and linezolid-loaded hybrid nanoparticles
demonstrated their ability to be retained in biofilms optimizing their antibacterial
performance [23]. Regarding the behavior of nanoparticles in anesthetic and anti-
inflammatory tests, tetracaine-loaded SLN exhibited prolonged antinociceptive
effect leading to better control of pain [26].
Finally, the possibilities to get target particles prepared by the nanoprecipitation
technique have been opened from the research works of Jeannot et al. [59] and
Dehaini et al. [7] who investigate hyaluronan and folate as receptors chemically
bonded to the polymer obtaining promising results for cancer therapies.
6. Conclusions
Nanoprecipitation is a simple, energy-efficient, and versatile method to entrap
active molecules into carriers at the submicron and nanometric levels being the
most common developments those oriented to obtain polymer, lipid, and hybrid
particles. As the knowledge on the in vivo behavior of nanocarriers progresses and
the need to produce them at the industrial scale demands for greater efficiency, the
technique and the used starting materials have been optimized to improve the
characteristics of the carriers and the control and standardization of continuous
processes. In this way, sophisticated devices have been proposed to get sizes lower
than 100 nm and the procedure has been refined, either through the chemical
modification of polymers or through the careful definition of the work conditions,
leading to particles entrapping hydrophobic and hydrophilic molecules, or
exhibiting a targeted performance, a positive charge on their surface, or behaviors
as stealth carriers. Moreover, the hybrid nanoparticles are promising drug delivery
systems where the advantages of both polymeric and lipid particles are harnessed in
their design to offer major drug loadings, slow drug-release patterns, and better
pharmacokinetic properties. Regardless of the type of carrier, nanoprecipitation
seems to be appropriate to obtain safe particles. Even using solvents characterized
by inherent toxicity, the satisfactory results achieved by safety tests support their
applicability in pharmaceutics. On this basis, it is expected that research on
nanoprecipitation will continue looking for innovative solutions to the challenges
facing current and future medicine. Some of the findings reported by different
research teams and summarized in this chapter provide valuable insights regarding
the potentialities of this technique in this respect.
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